In summary, a critical role for Stat5 in molecular and clinical progression of prostate cancer to castrate-resistant and metastatic disease has been established, and Stat5 has been shown to play a key role in pathogenesis of myeloproliferative disorders. Here, STAT5A is linked to metastatic neoplasm.